AI has the potential to transform the entire drug lifecycle, accelerating innovation across the pharmaceutical, biotech and medical device sectors.
Artificial intelligence is driving significant change across the life sciences industry, giving researchers, scientists and pharmaceutical manufacturers access to rapid analysis of vast amounts of data. This is enabling faster research and development processes, more efficient clinical and manufacturing workflows, and increasingly personalised therapeutic approaches.
For the pharmaceutical, biotech and medical device sectors, AI presents major opportunities across drug and device development and laboratory operations as well as advanced manufacturing environments. These developments are also prompting companies to reassess laboratory layouts, cleanroom strategies, technical infrastructure and wider real estate portfolios to support more agile, data-driven operations.
As the industry evolves, AI is expected to play an increasingly important role in improving efficiency, supporting innovation and helping organisations respond to growing regulatory, operational and technological complexity.
We’ll be there: Meet Deerns at the 65th AFI Symposium Rimini
We’ll be at the AFI Symposium, taking part in some of these exciting discussions.
Division Director Cosimo Verteramo and Business Development Manager Diego Di Lorenzo from our Life Sciences & Electronics Division will be available throughout the event to share news of our latest projects and explore the latest industry innovations and developments.
Stand 43
10 – 12 June
Palacongressi di Rimini, Italy
Join us to discover how Deerns is supporting forward-thinking companies in the design and optimisation of laboratories, cleanrooms and advanced technical facilities that are ready to support the next generation of AI-enabled innovation.
Find out more about our Life Sciences & Electronics services.
